Related Experiment Videos
Acute myocardial infarction in diabetic patients in the thrombolytic era
1Department of Cardiology, General Hospital, Birmingham, UK.
Insights
Thrombolytic therapy significantly benefits diabetic patients experiencing acute myocardial infarction, reducing both mortality and left ventricular failure. However, diabetic patients still face a poorer prognosis compared to non-diabetic individuals.
Area of Science:
- Cardiology
- Diabetology
- Medical Therapy
Background:
- Diabetic patients with acute myocardial infarction (AMI) have historically faced worse outcomes.
- The introduction of thrombolytic therapy aimed to improve treatment efficacy for AMI.
Purpose of the Study:
- To evaluate the benefits of thrombolytic therapy in diabetic versus non-diabetic patients with AMI.
- To compare in-hospital mortality and morbidity rates before and after the routine implementation of thrombolytic therapy.
Main Methods:
- Retrospective study comparing patient data from 1984-1987 (pre-thrombolytic therapy) and 1990-1992 (routine thrombolytic therapy).
- Analysis included diabetic and non-diabetic patients admitted to the coronary care unit with AMI.
- In-hospital mortality and incidence of left ventricular failure were assessed.
Main Results:
- Non-diabetic patients saw mortality decrease from 17% to 8.5% (49% reduction) and left ventricular failure from 22% to 8% (52% reduction).
- Diabetic patients experienced a mortality reduction from 30% to 17% (42% reduction) and left ventricular failure from 39% to 21% (45% reduction).
- Despite benefits, diabetic patients maintained a worse prognosis post-thrombolytic therapy.
Conclusions:
- Thrombolytic therapy offers significant advantages for diabetic patients with AMI, improving survival and reducing complications.
- Diabetic patients with AMI continue to have a less favorable prognosis than their non-diabetic counterparts, even with effective treatment.
- Further research into optimizing AMI care for diabetic populations is warranted.
Abstract:
To examine the benefits of thrombolytic therapy in diabetic patients with acute myocardial infarction a retrospective study of all diabetic and non-diabetic patients with acute myocardial infarction admitted to the coronary care unit of the General Hospital, Birmingham between January 1984 and December 1987 was made and findings compared to corresponding groups admitted between January 1990 and May 1992 when thrombolytic therapy was routine. In-hospital mortality and morbidity were assessed in 208 diabetic and 1029 non-diabetic patients with acute myocardial infarction admitted 1984 and 1987 and in 115 diabetic and 501 non-diabetic patients with myocardial infarction between January 1990 and May 1992. Following the introduction of thrombolytic therapy, there was a reduction in mortality among non-diabetic patients from 17% to 8.5%; p < 0.001 (observed reduction: 49%; 95% CI: 30-70%) and in the incidence of left ventricular failure (from 22% to 8%, p < 0.1 (observed reduction: 52%; 95% CI: 40-85.5%). Diabetic patients showed a reduction in mortality from 30% to 17%; p = 0.02 (observed reduction: 42%; 95% CI: 9.4-73.8%) and in the incidence of left ventricular failure from 39% to 21%; p < 0.01 (observed reduction: 45%; 95% CI: 20.3-72.5%). Thrombolytic therapy confers a major benefit on diabetic patients with acute myocardial infarction, although this group remains at a prognostic disadvantage compared to non-diabetic patients.